BOVILIS® COVEXIN® 8
Clostridium Chauvoei-Septicum-Haemolyticum-Novyi-Tetani-Perfringens Types C & D Bacterin-Toxoid
Product Description
Shown to be effective for the vaccination of healthy cattle and sheep against disease caused by Clostridium chauvoei, C. septicum, C. novyi Type B, C. haemolyticum, C. tetani and C. perfringens Types C and D.
Indications
This product has been shown to be effective for the vaccination of healthy cattle and sheep against disease caused by Clostridium chauvoei, C. septicum, C. haemolyticum, C. novyi, C. tetani, and C. perfringens Type C & D.
Although C. perfringens Type B is not a significant problem in North America, immunity is derived from a combination of the Type C (beta) and Type D (epsilon) fractions.
Diseases
Dosage
CATTLE: 5 mL injection administered subcutaneously or intramuscularly followed by a second 5 mL dose given six weeks later. Revaccinate annually with 5 mL prior to periods of extreme risk or parturition.
SHEEP: 5 mL injection administered subcutaneously followed by a second 2 mL dose given six weeks later. Revaccinate annually with 2 mL prior to periods of extreme risk or parturition.
Supplied
1 x 50 mL (Cattle 10 doses, Sheep 10 primary/25 booster doses)
1 x 250 mL (Cattle 50 doses, Sheep 50 primary/125 booster doses)
Preservatives
Contains Thimerosal as a preservative.
Caution
Store at 2°-8°C (35°-46°F). Do not freeze. Use entire contents when first opened. Do not mix with other products. Do not vaccinate within 21 days before slaughter. This product has not been tested in pregnant cattle. Local reactions may be observed following subcutaneous administration to cattle. Anaphylactoid reactions may occur following use.
Antidote: Epinephrine. In case of human exposure, contact a physician.
FOR ANIMAL USE ONLY.
Contact
U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3573
For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov
For additional information, please see the product label.
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global